Is the Blood Supply Safe? History, Recalls, and Current Risks

The U.S. blood supply is widely considered the safest in the world — and that is true in important ways. The layered testing and screening systems in place today have reduced transfusion-transmitted disease risk to very low levels. But “safe” is not the same as “risk-free,” and the history of blood supply safety is one of catastrophic failures followed by hard-won improvements. Patients have a right to understand both.

How Safe Is the Blood Supply Today?

Current transmission risks for the most serious blood-borne pathogens, per screened unit transfused in the United States:

These numbers reflect a five-layer safety system detailed in the FDA blood safety regulations article, including donor screening questionnaires, mandatory pathogen testing, deferral registries, quarantine protocols, and incident reporting.

A 1996 Congressional report described the blood supply as “safer than it has ever been” — a phrase that remains accurate today and has only strengthened as nucleic acid amplification testing (NAT), pathogen reduction technologies, and computerized tracking have been implemented. But the same report identified ongoing systemic problems that context requires us to acknowledge.

What Happened During the HIV and Hepatitis C Crisis?

The Scale of the Disaster

In the early 1980s, approximately 10,000 hemophiliacs contracted HIV from contaminated clotting factor concentrates, along with approximately 12,000 other patients through blood transfusions. The blood supply was not tested for HIV until 1985 — six years after the epidemic began.

Separately, roughly 300,000 people acquired hepatitis C from blood transfusions before the first HCV screening test was introduced in 1990. Many still don’t know they’re infected.

These were not simply the result of an unknown pathogen. A 1995 Institute of Medicine report, followed by a 1996 Congressional investigation (House Report 104-746), found that regulatory failures, industry resistance to proactive testing, and poor interagency coordination at the FDA, CDC, and NIH contributed to thousands of preventable infections.

What the Congressional Investigation Found

The 1996 House of Representatives investigation identified five critical systemic failures:

1. Inadequate public communication: Patients were not adequately informed about transfusion risks or alternatives like autologous (self-donated) blood. The report found that patients were “permitted to believe there is no risk in blood transfusions.”

2. FDA regulatory failures: The Blood Products Advisory Committee (BPAC) — the body advising the FDA on blood safety — demonstrated dysfunction. At one point, the committee voted against recommending HIV antigen testing despite evidence it could prevent infections. Consumer representation was inadequate: only 2–3 voting consumer members among 17 total.

3. Deficient recall systems: Despite 15 years since AIDS emerged as a blood supply threat, the FDA had not established effective product recall notification systems. One documented case involved a hemophiliac child whose family was not notified of a recalled product for six months.

4. Advance inspection notice: The FDA was found to be giving some plasma fractionation companies advance warning of inspections — a practice inconsistent with FDA’s approach to other regulated industries and potentially allowing facilities to temporarily correct violations before inspectors arrived.

5. Large plasma pool risks: Some factor concentrates were manufactured from pools of up to 60,000 donors. A single infected unit could contaminate an entire pool. Larger pools dramatically increased the probability that any given patient would be exposed to an infected donation.

What Congress Recommended

The investigation produced seven major recommendations:

1. Establish statutory authority for the Blood Safety Committee to ensure continuity across administrations
2. Create a compensation system for those harmed by blood products, modeled on vaccine compensation programs
3. Notify the estimated 300,000 people infected with hepatitis C before 1990 and provide treatment information
4. Develop standardized informed consent documents explaining transfusion risks and alternatives
5. Fix recall notification procedures for healthcare providers and patients
6. Stop the practice of giving advance inspection notice to plasma fractionators
7. Limit plasma pool sizes to reduce exposure risk per patient

Not all of these recommendations were fully implemented — a source of ongoing criticism from patient advocacy groups.

What Are Blood Recalls and How Do They Work?

Why Recalls Happen

Blood recalls occur when units that have already been tested, processed, and in some cases distributed are identified as potentially unsafe. Common triggers include:

• A donor returns within months and tests positive for an infection (suggesting they were in the window period at donation)
• New information links a donor to a disease not tested at the time of donation
• A laboratory testing error is discovered after distribution
• A manufacturing or storage deviation that could compromise product safety

FDA enforcement reports document these events weekly. The critical phrase from BloodBook.com’s coverage captures the stakes: these are blood products “already ‘tested,’ then processed and then in some cases re-processed, AND DISTRIBUTED for use by humans.”

What Happens When Blood Is Recalled

When a recall is initiated, blood banks notify hospitals that received the affected units. Hospitals are then supposed to notify patients — a chain of communication that has historically been unreliable. The 1996 Congressional report specifically identified the six-month delay in notifying a hemophiliac child’s family as evidence that the notification system was inadequate.

What Blood Withdrawal Notices Look Like

Standard blood withdrawal notices are formal communications sent to patients or families when received blood has been linked to a potentially contaminated donation. They typically include:

• Identification of the specific product and lot number
• The nature of the potential contamination concern
• Risk context (often noting that “there is little reason for concern” or “almost no real risk” of transmission)
• Recommendations to consult a physician and monitor for symptoms
• Contact information for the blood bank’s information line

These notices reflect appropriate caution — not confirmed infection. Most recalled units do not actually transmit disease. But the notification itself is an important patient right.

What Are the Ongoing Risks That Can’t Be Fully Eliminated?

The Window Period

Every blood test has a window period — the interval between when infection occurs and when it becomes detectable. NAT testing has shortened the HIV window period to approximately 9–11 days and the HCV window period to 7–10 days. But blood donated on day 1–8 of an HIV infection may still test negative and pass into the supply.

Bacterial Contamination

Platelets, stored at room temperature for up to five days, are particularly susceptible to bacterial growth. For years, no routine cost-effective bacterial screening was standard practice. Bacterial contamination causes an estimated 30 deaths annually in the U.S. — a number that prompted the introduction of pathogen reduction technologies for platelet products.

Emerging Pathogens

Novel infectious agents — those not yet identified or not currently screened — represent the unknown category of risk. The Congressional report specifically mentioned Creutzfeldt-Jakob Disease (CJD/vCJD), parvovirus B19, hepatitis G, and Chagas disease as concerns the blood safety system needed to address. More recently, West Nile virus, Zika, and Babesia have been added to screening panels.

Regional Variation in Risk

Data from the mid-1990s showed that geographic location affected transfusion disease risk. The Southeast showed the highest risk at approximately 1 in 150,000, while the Central region was lowest at 1 in 1,100,000. Blood transportation across regions and improved standardization have since reduced this variation.

What Do Patients Have the Right to Know?

The informed consent framework requires that patients facing blood transfusions be told:

• The nature of the proposed transfusion
• Associated risks and benefits
• Available alternatives, including autologous (self-donated) blood
• The likely outcome if they decline transfusion
• What success looks like and what recovery involves

The 1996 Congressional report was explicit: “the public is not well served if patients are permitted to believe there is no risk in blood transfusions.” Transparency — even about very small risks — builds trust and enables genuinely informed decisions.

For detail on how specific pathogens like hepatitis C enter the blood supply, see hepatitis C and blood transfusion. For the regulatory mechanisms in place to prevent contaminated blood from reaching patients, see FDA blood safety regulations.